Results 61 to 70 of about 21,820 (216)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

, 2013
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-
Hoban, Daryl J., Zhanel, George G., Karlowsky, James A., Adam, Heather, Lawson, Christopher D., Schweizer, Frank, Gin, Alfred S., Lynch, Joseph P., Zelenitsky, Sheryl, Denisuik, Andrew, Rubinstein, Ethan, Lagacé-Wiens, Philippe R. S.   +11 more
core   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari, Sepideh Elyasi, Farshad Abedi   +2 more
wiley   +1 more source

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

Frontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang, Yun Han, Yinshan Wu, Feng Guo, Zhenwei Yu   +4 more
doaj   +1 more source

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections [PDF]

, 1983
Thirty-six urological patients (21 male, 15 female) aged 21 to 83 years with complicated and/or hospital-acquired urinary tract infections due to sensitive bacteria were treated with ceftazidime intravenously with a daily dose of 2 g bd over 5 to 17 days.
Kurt G. Naber, Horst Grobeckerf, Kees, Frieder K., Naber, K. G., Grobecker, H., Frieder Keesf   +5 more
core   +1 more source

Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China

MedComm, Volume 7, Issue 8, August 2026.
Using 16,040 stool samples from healthy individuals across 30 Chinese provinces (2016–2024), we performed longitudinal genomic surveillance of carbapenem‑resistant Klebsiella pneumoniae (CRKP) colonizing the gut. We reveal rising community CRKP prevalence, especially in southern China, a shift from blaKPC‐2 to plasmid‑borne blaNDM‐5 on IncHI2/IncHI2A ...
Zelin Yan, Yan Li, Yi Sun, Qiaoling Sun, Congcong Liu, Yanyan Zhang, Yuchen Wu, Hongwei Zhou, Shangshang Qin, Gongxiang Chen, Ruichao Li, Rong Zhang   +11 more
wiley   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

International Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source

Tissue and Serum Concentrations of Time‐Dependent Antibiotics in Infected Diabetic Foot Ulcers by Bolus or Continuous Administration: The Randomised DFIATIM Trial

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The clinical effectiveness of antibiotic (ATB) therapy in patients with infected diabetic foot ulcers (iDFUs) depends on achieving sufficient ATB concentrations in both serum and peripheral tissues. This study evaluated the availability and bactericidal activity of the time‐dependent ATBs—ceftazidime (CTZ) and amoxicillin/clavulanate (AMC)
Radka Jarošíková, Dominika Sojáková, Simona Antalová, Petr Tůma, Jan Polák, Michal Dubský, Andrea Němcová, Veronika Wosková, Pavol Beca, Istvan Modos, Jan Mareš, Jakub Mrázek, Chahrazed Mekadim, Markéta Skružná, Vladimíra Fejfarová   +14 more
wiley   +1 more source

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible ...
Wright W. Nichols, Gregory G. Stone, Paul Newell, Helen Broadhurst, Angela Wardman, Merran MacPherson, Katrina Yates, Todd Riccobene, Ian A. Critchley, Shampa Das   +9 more
openaire   +2 more sources